

## SIGNATURE PRIORITY

# Cancer Neuroscience Program

## Unmet need, unmatched leadership

MD Anderson Cancer Center has launched a first-of-its-kind Cancer Neuroscience Program, uniting world-renowned experts in neuroscience and oncology in pursuit of one transformative goal: to uncover how cancer and the nervous system interact and translate that knowledge into better treatments and quality of life for patients and survivors.

Researchers have found that the nervous system plays a much larger role in cancer than previously thought, and it directly influences cancer development, progression, treatment response and side effects. Connected to every aspect of the body, the nervous system holds answers for all types of cancers, and the Cancer Neuroscience Program focuses on unlocking them.

Much as immunotherapy transformed oncology two decades ago, cancer neuroscience emerges as the next frontier — poised to revolutionize cancer research and patient care. To advance this pioneering initiative, philanthropic support is needed to address these mission critical areas:

- **Define the biological interactions between the nervous system and cancer**
- **Discover breakthrough therapies for all ages and cancer types**
- **Protect the brain and nervous system during and after treatment**
- **Improve quality of life and survivorship by promoting nervous system health**

## **MISSION**

Eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public

## **5 THINGS TO KNOW ABOUT MD ANDERSON**

- MD Anderson Cancer Center is ranked No. 1 in the nation for cancer care in U.S. News & World Report's "Best Hospitals" survey and has been named one of the nation's top two hospitals for cancer care since the survey began in 1990
- Saw 187,000 patients, completed 1.7 million outpatient visits and delivered \$346 million in uncompensated care in the past fiscal year
- Home to the world's largest cancer clinical trials program
- Invested \$1.3 billion in research in the past fiscal year
- Received 188 patents and tested 27 drugs that received Food and Drug Administration (FDA) approval in the past fiscal year

To learn more, visit [MDAnderson.org/QuickFacts](https://MDAnderson.org/QuickFacts)

